BrainStorm Wins Eighth Grant From Office Of Chief Scientist

December 16, 2014 | The Israeli company BrainStorm Cell Therapeutics, a developer of stem cell treatments for neurodegenerative diseases, announced that it was awarded a grant of $1.1 million from Israel’s Office of the Chief Scientist. This is already the eighth year that the company has received a grant of support from the Office of the Chief Scientist. According to the company, the funds will be put towards the continued development of NurOwn, the company’s mesenchymal stem cell-based platform for the treatment of neurodegenerative diseases and the Phase II clinical program in amyotrophic lateral sclerosis (ALS). The Office of the Chief Scientist has provided grants worth $4.1 since 2007 to BrainStorm to support the development of NurOwn.